Auf dem Laufenden bleiben
E-Mail-Adresse hinterlassen, um über neue Funktionen von Erikonomie informiert zu werden. Kein Tracking, jederzeit abbestellbar.
Novartis AG erreicht aktuell einen Erikonomie-Score von 57 von 100 Punkten – eine automatisiert berechnete, rein deskriptive Kennzahl aus Profitabilität, Bewertung, finanzieller Gesundheit, Dividende und weiteren Bereichen.
Novartis AG wird von Erikonomie dem Sektor „Gesundheitswesen" zugeordnet.
Die aktuelle Dividendenrendite von Novartis AG liegt bei rund 2.9 %. Nach den bei Erikonomie verfügbaren Daten wurde die Dividende seit 10 Jahren in Folge nicht gekürzt.
KGV 23.32 liegt 28.2 % unter dem Sektor-Median (32.48). Rein deskriptiver KGV-Vergleich, keine Kauf- oder Verkaufsempfehlung.
Der Kurs von Novartis AG ist in den letzten rund 12 Monaten um 22.6 % gestiegen.
Nein. Erikonomie liefert ausschließlich automatisiert berechnete, allgemeine Informationen zu öffentlich verfügbaren Finanzkennzahlen – keine Kauf- oder Verkaufsempfehlung und keine individuelle Anlageberatung. Der Erikonomie-Score und alle weiteren Kennzahlen sind rein deskriptiv.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Stand: gerade eben aktualisiert
Erikonomie stellt ausschließlich allgemeine, automatisiert berechnete Informationen zu öffentlich verfügbaren Finanzkennzahlen bereit. Dies ist keine Anlageberatung, keine Anlagevermittlung und keine Kauf- oder Verkaufsempfehlung. Alle Angaben ohne Gewähr. Investitionsentscheidungen triffst du eigenverantwortlich.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
